← back to search

Alessandro Bittoni

IRCCS Humanitas Research Hospital · IT
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Pancreatic and Hepatic Oncology Research, and Cancer Genomics and Diagnostics.
h-index
27
citations
2,212
works
175
NIH funding
primary concept
Medicine
email

Recent publications

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
Annals of Oncology 2024cited by 67position: middledoi
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology 2024cited by 24position: middledoi
Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)
Cancers 2020cited by 32position: middledoi
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
Scientific Reports 2016cited by 35position: middledoi
MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Oncotarget 2015cited by 73position: middledoi
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma
Critical Reviews in Oncology/Hematology 2015cited by 42position: middledoi
Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials
Critical Reviews in Oncology/Hematology 2015cited by 27position: middledoi
LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy
Annals of Oncology 2015cited by 0position: middledoi
Second-line treatment in patients with FOLFIRINOX-refractory pancreatic adenocarcinoma (PDAC): Doublets or single-agent chemotherapy?
Journal of Clinical Oncology 2014cited by 3position: middledoi
Clinical Outcome of Elderly (>70Y) Advanced Pancreatic Cancer Patients Receiving Chemotherapy
Annals of Oncology 2014cited by 1position: middledoi
Single-Agent or Doublets As Second-Line Chemotherapy After Folfirinox in Patients with Locally Advanced or Metastatic Pancreatic Cancer
Annals of Oncology 2014cited by 1position: middledoi
Who Should Receive First-Line Folfirinox? Prognostic Factors in Locally Advanced or Metastatic Pancreatic Cancer Patients
Annals of Oncology 2014cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Stefano Cascinu · Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele9 papers (2014–2016)Daniele Santini · Azienda Ospedaliera Sant'Andrea9 papers (2014–2016)Nicola Silvestris · University of Bari Aldo Moro8 papers (2014–2020) · 7 papers (2014–2016) · 5 papers (2014–2015) · 5 papers (2014–2015) · 5 papers (2015–2020)Matteo Santoni · Istituti di Ricovero e Cura a Carattere Scientifico5 papers (2014–2015)Marco Russano · Università Campus Bio-Medico4 papers (2014–2014) · 4 papers (2014–2014)Alberto Zaniboni · Fondazione Poliambulanza Istituto Ospedaliero3 papers (2014–2014)V. Vaccaro · St Thomas' Hospital3 papers (2014–2014)Michele Reni · San Raffaele University of Rome3 papers (2015–2020)Michèle Milella · University of Verona3 papers (2014–2020) · 2 papers (2014–2015)Giuseppe Tonini · Campus Bio Medico University Hospital2 papers (2014–2015) · 2 papers (2015–2016) · 2 papers (2015–2016) · 2 papers (2014–2014) · 2 papers (2015–2015)